Aortic Surgery in Marfan Syndrome.
Marfan syndrome is a genetic connective tissue disorder affecting approximately 1 in 5,000 individuals, caused by mutations in the fibrillin-1 gene. The most life-threatening manifestation is aortic root dilation, which progresses over time and, if untreated, leads to aortic dissection or rupture — catastrophic events carrying 1-2% mortality per hour if not treated emergently. Prophylactic aortic root replacement has transformed Marfan syndrome from a condition with average life expectancy in the early 40s to one where patients routinely live into their 70s and beyond. The key surgical question for Marfan patients is the choice of operation: the Bentall procedure (composite graft with mechanical valve, requiring lifelong warfarin) versus the David procedure (valve-sparing aortic root replacement, preserving the native aortic valve and avoiding anticoagulation). The David procedure is technically more demanding but offers profound quality-of-life advantages, particularly for young patients who wish to avoid warfarin. Not all cardiac surgeons perform the David procedure, and outcomes are highly volume-dependent. Timing of prophylactic surgery is equally important. Current guidelines recommend surgery when the aortic root reaches 5.0 cm in Marfan patients (or 4.5 cm in certain high-risk subgroups), but the trajectory of growth and family history of dissection also inform the decision.
What the evidence shows.
Long-term data from the David procedure in Marfan patients shows excellent durability. A 2022 series from the Peter Munk Cardiac Centre (where Dr. Tirone David developed the procedure) reported 20-year freedom from aortic valve reoperation of 92% in Marfan patients — demonstrating that the native valve, when carefully preserved, functions well for decades. A multicenter Marfan registry analysis showed that prophylactic aortic root replacement (at the 5.0 cm threshold) carries operative mortality of 1-2% at experienced centers, compared to 15-25% mortality for emergency surgery for acute dissection. Beta-blocker therapy (propranolol or atenolol) and losartan have been shown to slow aortic root growth by approximately 50% in randomized trials, extending the time to surgical threshold. However, medical therapy does not eliminate the need for surgery — it delays it.
Current recommendations.
Current ACC/AHA aortic disease guidelines recommend: (1) prophylactic aortic root replacement when the aortic root reaches 5.0 cm in Marfan patients; (2) surgery at 4.5 cm in patients with rapid growth (more than 0.5 cm/year), family history of dissection at small aortic size, or significant aortic regurgitation; (3) the David procedure (valve-sparing root replacement) is preferred when the aortic valve leaflets are structurally normal and the surgeon has adequate experience; (4) lifelong surveillance of the remaining aorta after root replacement, as Marfan syndrome affects the entire aorta; (5) referral to a comprehensive aortic center with experience in hereditary aortopathies; (6) genetic counseling for family members.
Why this matters for your decision.
Marfan patients face a lifetime of aortic surveillance and may need multiple aortic operations. The initial surgical strategy — particularly whether the native aortic valve is preserved (David procedure) or replaced (Bentall procedure) — has enormous implications for quality of life, anticoagulation burden, and future surgical options. A second opinion from a Heart Team with expertise in hereditary aortopathies ensures the patient is aware of all surgical options and is directed to a surgeon with the specific expertise required for this technically demanding operation.
Need help with this decision?
Our Heart Team evaluates your specific situation with AI-augmented analysis and dual-physician review.